Anti-LINGO 1 Showing Promise Repairing Nerve Damage

Share this content:
Myelin
Myelin

HealthDay News -- An experimental drug appears to repair nerve damage seen in multiple sclerosis patients, results of an early trial suggest. The results are to be presented next week at the annual meeting of the American Academy of Neurology, April 18 to 25 in Washington, D.C. 

The trial was the second of three phases required for FDA approval of the drug, known as anti-LINGO-1.

Diego Cadavid, MD, who is with Massachusetts-based Biogen Idec, which makes the drug and funded the trial, and his colleagues gave 82 patients with acute optic neuritis high doses of steroids before randomly assigning them to anti-LINGO-1 or placebo. Every four weeks, patients received a dose of anti-LINGO-1 until six doses were given. Participants were then assessed every four weeks for six months. They underwent a final assessment at eight months.

The researchers found that people treated with anti-LINGO-1 had significantly improved nerve repair compared with people who received the placebo -- 34% greater at six months and 41 percent at eight months. Moreover, more than half of people treated with the drug saw a return to normal or near normal function, compared with 26% of patients who received the placebo.

"The hope for this drug is that in people who have multiple sclerosis, or any other disease that damages myelin, it will regenerate myelin that is lost," Cadavid told HealthDay. The researchers are now testing the drug in multiple sclerosis patients in hopes of seeing similar myelin regeneration. "A second phase 2 study in people with relapsing forms of multiple sclerosis is evaluating the clinical benefit of anti-LINGO-1 when used long-term in people with different degrees of multiple sclerosis disability," Cadavid said.

References

  1. Cadavid D, et al. Evidence of Remyelination with the Anti-LINGO-1 Monoclonal Antibody BIIB033 After Acute Optic Neuritis. Presented at: American Academy of Neurology Annual Meeting; April 18-25, 2015: Washington, D.C.
  2. AAN Press Release

You must be a registered member of Clinical Pain Advisor to post a comment.